Business Wire

BioAuxilium Research Launches New THUNDER™ TR-FRET Biomarker Assay Kits and an Enhanced Assay Development Service for Drug Discovery

Share

At the annual Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in San Diego, BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully validated assay kits to the biomedical research community, today announced the expansion of its no-wash THUNDER™ time-resolved Förster resonance energy transfer (TR-FRET) technology portfolio by introducing six new biomarker research assay kits, a Reader Control Kit, and an enhanced assay development service for drug discovery research.

BioAuxilium developed the new biomarker assays in response to customer requests for reliable cell-based assays that provide an alternative to expensive immunoassay platforms such as other TR‑FRET and bead-based assay technologies. The new offerings include a panel of six key mouse inflammatory cytokines (CCL-2/MCP1, IFN-beta, IFN-gamma, IL-2, IL-6, and TNF-alpha), expanding the company’s portfolio to a total of 100 cell-based assay kits (76 Cell Signaling Kinases, 23 Biomarkers, and a cAMP Assay). The ready-to-use Reader Control Kit allows users to assess in just 10 minutes the suitability of TR‑FRET compatible microplate readers to perform Europium-based TR-FRET measurements.

The new assay development service offers three types of custom assay solutions: labeling of antibodies with BioAuxilium’s proprietary TR-FRET fluorophores, custom assay development services, and custom kit development services. These comprehensive, yet flexible custom solutions are designed to fast-track assay development, while further reducing risk, turnaround time, and cost.

“BioAuxilium continues to make great strides with the expansion of the THUNDER™ TR-FRET technology portfolio, based on customer demand for high-performing, reliable yet affordable immunoassays,” said Jaime Padros, PhD, President, BioAuxilium Research. “In addition, our decades of experience developing and manufacturing drug discovery assays based on TR-FRET allow us to deliver results within turnaround times and at prices simply unattainable by any other custom assay development service.”

BioAuxilium’s THUNDER™ TR-FRET technology is a robust, proprietary platform based on a FRET pair showing an enhanced spectral compatibility and TR-FRET signal, best antibody pairs selected specifically for TR-FRET, and a panel of optimized lysis and assay buffers. In addition, the “add-incubate-read” protocol of the immunoassay platform, combined with its full compatibility with different TR-FRET readers, facilitates streamlined workflows and automation for high-throughput screening. All THUNDER™ TR-FRET assays are extensively validated to ensure specificity, sensitivity, reproducibility, and lot-to-lot consistency.

About BioAuxilium Research Inc.

BioAuxilium is a private Canadian biotechnology tool company founded by expert assay scientists. It focuses on developing and manufacturing top-quality, highly validated assay kits that accelerate drug discovery and basic research. BioAuxilium’s kits are based on its enhanced proprietary THUNDER™ TR‑FRET technology. They are offered at an outstanding value and are accompanied by information-rich datasheets and expert technical support. BioAuxilium also provides customized services in assay development on a contract basis. Their products and services are available directly to US- and Canada-based customers, and through the company’s network of international distributors.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jaime Padros, President
514-312-9033 ext. 101
jaime.padros@bioauxilium.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KnowBe4 Report Reveals Security Training Reduces Global Phishing Click Rates by 86%13.5.2025 15:00:00 EEST | Press release

KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today launched its “Phishing by Industry Benchmarking Report 2025” which measures an organization’s Phish-prone™ Percentage (PPP) — the percentage of employees likely to fall for social engineering or phishing attacks, indicating the organization’s overall susceptibility to phishing threats. This year’s report found a global average baseline PPP of 33.1%, meaning a third of employees interact with phishing simulations before taking part in best-practice security awareness training (SAT). The data underscores the significant impact of SAT in mitigating risk. The rapid decline in the global PPP following the implementation of training — falling by 40% in just three months and by a total of 86% after 12 months — demonstrates that ongoing, effective training leads to lasting behavior change and a substantial reduction in vulnerability to cybersecurity threats. This highlights the critic

Armis Announces New Global Technology Integration Partners to Bolster Organizations’ Cyber Resilience13.5.2025 15:00:00 EEST | Press release

Armis, the cyber exposure management & security company, today announced that it has added 10 global technology integration partners over the past quarter. These integrations increase the functionality and efficiency of organizations’ existing technology stacks with added benefits from Armis’ platform and solutions. “Relying on siloed security solutions is no longer enough to gain a comprehensive, real-time understanding of an organization’s attack surface,” said Nadir Izrael, CTO and Co-Founder at Armis. “Integrating Armis’ best-in-class platform with other leading vendors’ offerings empowers businesses to consolidate their technology stacks. By driving greater value in their security investments, organizations can ensure their entire attack surface is continuously defended and managed.” New Armis global technology integration partners include AnzenOT, Brinqa, ColorTokens, EasyVista, SaltyCloud, Salvador Tech, SIGA, Spectro Cloud, Stellar Cyber, and Synqly. From compliance to network

Kyriba Unveils Agentic AI TAI to Transform Finance with Security, Compliance & Trust13.5.2025 14:35:00 EEST | Press release

Kyriba, a global leader in liquidity performance, today introduced its agentic AI solution, TAI – a significant advancement in the safe, compliant use of generative AI in finance operations to improve productivity and efficiency amid continued economic uncertainty. Powered by Kyriba's embedded Large Language Model (LLM) and over 20 years of unmatched global liquidity data, TAI simplifies complex workflows, identifies risks with predictive analytics, and enhances data-driven decision-making across treasury, payments, risk management and working capital. Poised to transform finance and treasury operations without relying on third-party LLM integrations, TAI is a key component of Kyriba’s Trusted AI portfolio. This platform-wide approach prioritizes industry-leading data privacy while empowering enterprise leaders to make faster, smarter decisions with human judgement and responsibility at the center. Kyriba’s approach directly addresses the "Trust Gap" – the growing divide between the pr

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference13.5.2025 13:01:00 EEST | Press release

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 1 year following the event. About BeiGene BeiGene, which will change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need

IQM’s First Quantum Computer in Asia-Pacific Goes Online, Set to Open Office in Seoul13.5.2025 12:09:00 EEST | Press release

IQM Quantum Computers, a global leader in superconducting quantum computers, has announced expanding its presence in Asia-Pacific with a new office opening in South Korea in June 2025, following the installation of its first quantum system at Chungbuk National University (CBNU). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513710683/en/ From left to right: Ben Lee and Mikko Välimäki of IQM Quantum Computers, Professor Kim Kiwoong of Chungbuk National University, Jyri Järviaho, Ambassador of Finland to South Korea, Jaana Tuomi, of Enter Espoo, Guensuk Ko of CBIST The office in Seoul reinforces IQM’s dedication to collaborating with research and academic institutions, high-performance computing (HPC) centers, and enterprises in advancing quantum technology. It also supports South Korea in building a vibrant quantum ecosystem and achieving the goals of its national quantum strategy. As part of the expansion, IQM has appoin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye